SCHEMBL4095036

SCHEMBL4095036

CCOC(=O)c1c(N)sc2c1C1CCC2C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 9/20 0.56
ALDH1A1 P00352 14/20 0.55
MAPT P10636 10/20 0.55
HPGD P15428 10/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
FHIT P49789 1/20 0.51
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
KDM4E B2RXH2 4/20 0.48
ALOX15 P16050 3/20 0.48
HSD17B10 Q99714 3/20 0.48
TSHR P16473 2/20 0.48
ALOX12 P18054 1/20 0.48
MAPK1 P28482 2/20 0.47
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
POLB P06746 2/20 0.45
RECQL P46063 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4091390 0.75 RPS6KB1 (0.50) GAAALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL4084562 0.75 CNR2 (0.48) ALDH1A1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL4091337 0.73 CNR2 (0.49) ALDH1A1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL4080036 0.73 GAA (0.97) GAAALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL223094 0.73 ALDH1A1 (1.00) GAAALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL21603773 0.72 ALDH1A1 (0.61) GAAALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL21597781 0.70 ALDH1A1 (0.61) GAAALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL21597352 0.70 ALDH1A1 (0.58) GAAALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL8191511 0.70 ALDH1A1 (0.67) GAAALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL3911820 0.70 GAA (0.61) GAAALDH1A1MAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11492347-B2 Fused thiophene derivatives and their uses ENYO PHARMA (FR) 2022-11-08 US disclosed
EP-3749659-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 EP disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 US disclosed
CN-111954668-A Fused thiophene derivative and use thereof 埃尼奥制药公司 2020-11-17 CN disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 WO disclosed
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed
EP-1343561-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 GAA 4164/4885ALDH1A1 1504/4885MAPT 2527/4885
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH GAA 267/4885ALDH1A1 2143/4885MAPT 2107/4885
US-11492347-B2 Fused thiophene derivatives and their uses FTH1, SLC40A1, FECH GAA 267/4885ALDH1A1 2143/4885MAPT 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.